Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Type:
Grant
Filed:
June 27, 2018
Date of Patent:
October 1, 2019
Assignees:
Bristol-Myers Squibb Company, Université de Montréal
Inventors:
Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
Abstract: Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.
Type:
Grant
Filed:
February 9, 2016
Date of Patent:
September 17, 2019
Assignees:
UNIVERSITÉ DE MONTRÉAL, RSEM, LIMITED PARTNERSHIP
Inventors:
Claude Perreault, Diana Paola Granados, Jean-Sébastien Delisle, Pierre Thibault, Sébastien Lemieux
Abstract: There is provided a process for producing LiMXO4, comprising the steps of reacting a source of lithium, a source of M, and a source of X together, in a melted state at a reaction temperature between 900 to 1450 C, in the presence of an excess of (A) a solid-solid reducing couple having an oxygen partial process at equilibrium (pO2) comprised between 10?8 and 10?15 atm at said reaction temperature according to an Ellingham-Richardson diagram for oxides, or (B) one component of the solid-solid reducing couple together with a gas-gas reducing couple having an oxygen partial pressure equilibrium (pO2) between 10?8 and 10?15 atm at said reaction temperature according to an Ellingham-Richardson diagram of oxides, and under thermic equilibrium and thermodynamic equilibrium. There is also provided a LiMXO4 melt-solidified product free from off-composition impurities.
Type:
Grant
Filed:
May 26, 2015
Date of Patent:
August 13, 2019
Assignees:
JOHNSON MATTHEY PUBLIC LIMITED COMPANY, UNIVERSITÉ DE MONTRÉAL, LA CORPORATION DE L'ÉCOLE POLYTECHNIQUE DE MONTRÉAL
Inventors:
Michel Gauthier, Patrice Chartrand, Majid Talebi-Esfandarani, Pierre Sauriol, Mickael Dollé, Jasmin Dufour, Guoxian Liang
Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
Type:
Grant
Filed:
December 6, 2017
Date of Patent:
August 13, 2019
Assignees:
Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
Inventors:
David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
Abstract: A cutting guide for guiding a cut in a radius, the radius being adjacent to an ulna, the cutting guide comprising: a cut guiding portion, an opposed ulnar mounting portion and a linking portion extending therebetween; the cutting guide being delimited by a cutting guide peripheral surface defining a bone facing portion, the bone facing portion being contoured to match the shape of the radius and ulna.
Type:
Grant
Filed:
June 12, 2017
Date of Patent:
July 9, 2019
Assignees:
SOCOVAR, L.P., Colorado State University Research Foundation, Universite de Montreal
Inventors:
Vladimir Brailovski, Yvan Petit, Bertrand Lussier, Bernard Seguin, Martin Brummund, Anatolie Timercan
Abstract: The present invention relates to pharmaceutical compositions and combination therapies for treating patients having a neoplasm or a proliferative disorder, the combination comprises ribavirin, GDC-0449 and a chemotherapeutic agent, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides a combination therapy for treating patients having leukemia.
Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
July 2, 2019
Assignee:
UNIVERSITÉ DE MONTRÉAL
Inventors:
Guy Sauvageau, Yves Gareau, Rejean Ruel, Stephane Gingras, Iman Fares
Abstract: A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need en thereof an effective amount of a mitochondrial activity inhibitor, for example a class A electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT 1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.
Abstract: The present invention provides compounds of Formula I: wherein Y, AA, W, R3? R2, R4, R5, R6, R7, X1, X2, X3, X4 and X5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract: Described herein is a bioluminescence resonance energy transfer (BRET) based system and method to monitor ternary complex formation in real-time in live cells with high sensitivity and accuracy. This system transfers energy simultaneously between a luciferase donor and intermediate and terminal acceptors, appropriately chosen to also enable transfer from the intermediate to terminal acceptor while minimizing contaminating signals. The system may also be adapted for quaternary complex detection by including a protein complementation assay (PCA) component. The system is broadly applicable to the detection of any protein ternary/quaternary complex such as those involving nuclear receptors, GPCRs, Receptor Tyrosine Kinase (RTKs), multimeric enzymes or structural proteins.
Type:
Grant
Filed:
December 23, 2014
Date of Patent:
June 18, 2019
Assignee:
UNIVERSITÉ DE MONTRÉAL
Inventors:
David Cotnoir-White, Sylvie Mader, Étienne Gagnon, Michel Bouvier
Abstract: Methods and compositions for enhancing viral gene transfer, such as lentiviral gene transfer, and improving the efficacy of gene delivery to cells such as primitive hematopoietic cells, are described. These methods and compositions are based on the use of pyrimido[4,5-b]indole derivatives. Cell-based compositions and methods useful for therapeutic indications amenable to treatment with gene therapies, including hematopoietic stem cell therapies, are also described.
Type:
Grant
Filed:
September 17, 2015
Date of Patent:
April 30, 2019
Assignees:
UNIVERSITE DE MONTREAL, BRITISH COLUMBIA CANCER AGENCY BRANCH, FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Guy Sauvageau, Keith Richard Humphries, Hans-Peter Kiem, Iman Fares, Jalila Chagraoui
Abstract: A speech recognition method includes obtaining an acoustic sequence divided into a plurality of frames, and determining pronunciations in the acoustic sequence by predicting a duration of a same pronunciation in the acoustic sequence and skipping a pronunciation prediction for a frame corresponding to the duration.
Type:
Application
Filed:
July 18, 2018
Publication date:
April 25, 2019
Applicants:
Samsung Electronics Co., Ltd., Universite de Montreal
Inventors:
Inchul SONG, Junyoung CHUNG, Taesup KIM, Sanghyun YOO
Abstract: The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X1, X2, X3, X4, X5, Y, WR2, R3, R4, R5, R6, R7 and AA and other moieties are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Type:
Grant
Filed:
February 25, 2016
Date of Patent:
March 26, 2019
Assignees:
Universite De Montreal, Bristol-Myers Squibb Company
Inventors:
Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Shoshana L. Posy
Abstract: A novel method for human minor histocompatibility antigen (MiHA) discovery, novel MiHAs identified using this method, as well as uses of the novel MiHAs, are described. One of the features of the novel method is the inclusion of personalized translated transcriptome and/or exome in the database used for peptide identification by mass spectroscopy (MS). Candidate MiHAs are identified by comparing the personalized transcriptome and/or exome to a reference genome and/or to the transcriptome and/or exome of an HLA-matched subject.
Type:
Grant
Filed:
October 20, 2016
Date of Patent:
March 26, 2019
Assignee:
UNIVERSITÉ DE MONTRÉAL
Inventors:
Claude Perreault, Pierre Thibault, Sébastien Lemieux, Diana Paola Granados, Sriranganadane Dev, Mohamed Tariq Daouda, Olivier Caron-Lizotte
Abstract: It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.
Type:
Application
Filed:
May 31, 2017
Publication date:
March 21, 2019
Applicants:
UNIVERSITE DE MONTREAL, UNIVERSITE DE MONTREAL
Inventors:
Guy SAUVAGEAU, Iman FARES, Jalila CHAGRAOUI
Abstract: The present invention provides imidazopyridazine compounds or imidazothiadiazole compounds of Formula I having the structure: (I) wherein X1, X2, X3, X4, X5, Y, W, R1, R2, R3, R4, R5 and (II) are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract: The present invention relates to an immunogenic composition comprising polysaccharide-protein conjugates wherein each conjugate contains a capsular polysaccharide prepared from Streptococcus suis serotypes 1, 2, 7 and/or 9 or any other serotype conjugated to a carrier protein. The immunogenic composition is useful for the protection of disease in an animal subject.
Type:
Application
Filed:
October 6, 2016
Publication date:
September 27, 2018
Applicants:
Boehringer Ingelheim Vetmedica, Inc., Université de Montréal, Université du Québec à Montréal
Inventors:
Marcelo GOTTSCHALK, Guillaume GOYETTE-DESJARDINS, Jennifer Anne Kempker, Axel NEUBAUER, René ROY, Mariela SEGURA, Tze Chieh SHIAO
Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
Type:
Application
Filed:
September 26, 2016
Publication date:
September 20, 2018
Applicants:
The Regents of the University of California, The Université de Montréal
Abstract: Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
Type:
Grant
Filed:
July 15, 2014
Date of Patent:
September 18, 2018
Assignees:
The Regents of the University of California, The Université de Montréal
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
August 14, 2018
Assignees:
Bristol-Myers Squibb Company, Universite de Montreal
Inventors:
Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller